Novavax's COVID vaccine brought in sales of $38.21 million for the third ... 2024 Healthcare & Pharmaceuticalscategory Teen ...

Vaccine production is nearly three years behind schedule at a federally owned plant in Montreal and the future of a deal ...

Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...

Health officials say eligible residents can receive the COVID-19 vaccine at the same time as or at any time before or after ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

Eric Joseph has given his Sell rating due to a combination of factors affecting Novavax’s current and future performance. One major concern is the company’s underwhelming market share for its COVID ...

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...